Populate, a management platform owned by mixed-use developer Socius, has appointed Dr Angela Kukula as Director of Science and Innovation. 

Dr Kukula was previously Chief Executive of MedCity and Director of Life Sciences at London & Partners, where she championed London’s life sciences sector on the global stage. She reportedly played a central role in connecting growing companies with investors, research institutions, healthcare partners and the developers creating space for the sector to thrive. Earlier in her career, she was Commercial Director at Chelsea and Westminster Hospital NHS Foundation Trust and held a series of roles at the Institute of Cancer Research focused on the commercialisation of research and business growth. 

In her new role, Dr Kukula will focus on expanding Populate’s offer in the science and technology sectors, advising property owners, research institutions and corporate occupiers on how to create ecosystems, commercial partnerships and the campus infrastructure that helps to unlock innovation.

London Cancer Hub 

One of her initial projects will include the London Cancer Hub, where Populate is working with Socius and Aviva Capital Partners, as well as the Institute of Cancer Research and Royal Marsden NHS Foundation Trust, to enhance the campus environment to bring together researchers and clinicians with oncology companies and investors.   

Olaide Oboh, Managing Director, Populate, said: “As we continue to enhance the ecosystem at the London Cancer Hub and expand further in the science and technology sector we are excited to welcome Angela as Director of Science and Innovation to help campuses and emerging clusters across the UK develop and thrive.”   

Dr Kukula said: “The London Cancer Hub has an exceptional foundation in the research of the ICR and the clinical expertise of The Royal Marsden and there is an opportunity to enhance the ecosystem around them, connecting researchers and clinicians with companies, funders and the partners who can develop promising ideas into treatments for patients.”